Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Preclinical safety evaluation in murine tumor models

YL Yuehua Liu
XN Xiaoqian Nie
XY Xingyun Yao
HS Huafeng Shou
YY Yang Yuan
YG Yun Ge
XT Xiangmin Tong
HL Hsiang-Ying Lee
XG Xiaofei Gao
request Request a Protocol
ask Ask a question
Favorite

C57BL/6 mice were subcutaneously injected with 1 × 105 MC38-HPV16 tumor cells. On the second day after tumor inoculation, the mice were treated with PBS, mEry, or MHC-I‒E6‒mEry i.v. twice a week. On day 11, serum samples were collected for analysis. For the LPS positive control group, mice were i.p. injected with 5 mg/kg LPS and serum samples were collected 6 h later. The concentrations of IFN-γ (Absin, abs520007), IL-6 (Proteintech, KE10007), and TNF-α (Proteintech, KE10007) in serum were quantitatively analyzed by ELISA assay. Simultaneously, serum ALT levels were also monitored (Solarbio, BC1555). The data shown are representative of two independent experiments.

Copyright and License information: The Author(s) ©2024
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A